The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Summary

SY-009 is a novel compound that inhibits sodium glucose cotransporter-1 (SGLT-1). The preclinical and phase 1 clinical trial data support to carry out phase II clinical trial in diabetes subjects.

Timeline

Start

2022-07-01

Primary completion

2023-06-30

Completion

2023-10-01

Drugs

Indications